{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:30:41Z","timestamp":1790231441488,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2020.00654","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T08:34:33Z","timestamp":1600331673000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Fibroblast Growth Factor-21 to Adiponectin Ratio: A Potential Biomarker to Monitor Liver Fat in Children With Obesity"],"prefix":"10.3389","volume":"11","author":[{"given":"Emir","family":"Tas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiawei","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kori","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Buchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva C.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Oden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"B\u00f8rsheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean H.","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Dranoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American society of pediatric gastroenterology, hepatology nutrition","volume":"64","author":"Vos","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of non-alcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology."},{"key":"B3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.cgh.2016.08.028","article-title":"Nonobese fatty liver disease","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cld.2017.08.010","article-title":"Nonalcoholic fatty liver disease and metabolic syndrome","volume":"22","author":"Kim","year":"2018","journal-title":"Clin Liver Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J Intern Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1053\/j.gastro.2018.04.014","article-title":"Magnetic resonance imaging proton density fat fraction associates with progression of fibrosis in patients with nonalcoholic fatty liver disease","volume":"155","author":"Ajmera","year":"2018","journal-title":"Gastroenterology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e127902","DOI":"10.1172\/jci.insight.127902","article-title":"Human PNPLA3-I148M variant increases hepatic retention of polyunsaturated fatty acids","volume":"4","author":"Luukkonen","year":"2019","journal-title":"JCI Insight."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1007\/s00330-019-06072-4","article-title":"Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"29","author":"Gu","year":"2019","journal-title":"Eur Radiol."},{"key":"B11","volume-title":"Non-alcoholic Fatty Liver Disease: Assessment and Management","year":"2016"},{"key":"B12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"254S","DOI":"10.3945\/ajcn.2009.28449B","article-title":"Fibroblast growth factor 21: from pharmacology to physiology","volume":"91","author":"Kliewer","year":"2010","journal-title":"Am J Clin Nutr."},{"key":"B14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e12828","DOI":"10.14814\/phy2.12828","article-title":"Acute exercise increases fibroblast growth factor 21 in metabolic organs and circulation","volume":"4","author":"Tanimura","year":"2016","journal-title":"Physiol Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1210\/er.2017-00016","article-title":"Fibroblast growth factor 21-metabolic role in mice and men","volume":"38","author":"Staiger","year":"2017","journal-title":"Endocr Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/jmcb\/mjw013","article-title":"The FGF21-adiponectin axis in controlling energy and vascular homeostasis","volume":"8","author":"Hui","year":"2016","journal-title":"J Mol Cell Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.mce.2011.05.003","article-title":"The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes","volume":"342","author":"Zhang","year":"2011","journal-title":"Mol Cell Endocrinol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1172\/JCI67353","article-title":"Interplay between FGF21 and insulin action in the liver regulates metabolism","volume":"124","author":"Emanuelli","year":"2014","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1210\/jc.2013-1250","article-title":"Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage","volume":"98","author":"Giannini","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"key":"B21","volume-title":"Role of Plasma FGF21 as a Biomarker for Nonalcoholic Fatty Liver Disease (NAFLD) and Steatohepatitis (NASH): The Liver Meeting 2013: American Association for the Study of Liver Diseases (AASLD)","author":"Bril","year":"2013"},{"key":"B22","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J Hepatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes."},{"key":"B25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 Analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity."},{"key":"B28","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1249\/01.mss.0000487979.68551.d7","article-title":"Validating inbody\u00ae 570 multi-frequency bioelectrical impedance analyzer versus DXA for body fat percentage analysis","volume":"19","author":"Miller","year":"2016","journal-title":"J Exerc Physiol Online Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1007\/s00261-015-0506-9","article-title":"Feasibility of and agreement between MR imaging and spectroscopic estimation of hepatic proton density fat fraction in children with known or suspected nonalcoholic fatty liver disease","volume":"40","author":"Achmad","year":"2015","journal-title":"Abdom Imaging."},{"key":"B30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1148\/radiol.2493080217","article-title":"Quantification of liver fat content: Comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy","volume":"250","author":"Guiu","year":"2009","journal-title":"Radiology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.ejrad.2015.05.001","article-title":"Liver fat quantification: comparison of dual-echo and triple-echo chemical shift MRI to MR spectroscopy","volume":"84","author":"Satkunasingham","year":"2015","journal-title":"Eur J Radiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1177\/1756283X16656735","article-title":"Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis","volume":"9","author":"Patel","year":"2016","journal-title":"Therap Adv Gastroenterol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1210\/jc.2012-1221","article-title":"Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis","volume":"97","author":"Reinehr","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12944-018-0852-z","article-title":"Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits","volume":"17","author":"Ok","year":"2018","journal-title":"Lipids Health Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/hep.23129","article-title":"Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss","volume":"50","author":"Johnson","year":"2009","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"key":"B37","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7570\/jomes.2017.26.3.204","article-title":"Serum FGF21 levels in obese Korean children and adolescents","volume":"26","author":"Baek","year":"2017","journal-title":"J Obes Metab Syndr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jhep.2012.10.029","article-title":"High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: A 3-year prospective study in China","volume":"58","author":"Li","year":"2013","journal-title":"J Hepatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e24895","DOI":"10.1371\/journal.pone.0024895","article-title":"Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study","volume":"6","author":"Yan","year":"2011","journal-title":"PLoS ONE."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1042\/bst0301064","article-title":"Regulation of fatty acid synthesis and oxidation by the AMP-activated protein kinase","volume":"30","author":"Hardie","year":"2002","journal-title":"Biochem Soc Trans."},{"key":"B42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bbrc.2009.02.131","article-title":"Adiponectin suppresses hepatic SREBP1c expression in an AdipoR1\/LKB1\/AMPK dependent pathway","volume":"382","author":"Awazawa","year":"2009","journal-title":"Biochem Biophys Res Commun."},{"key":"B43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1530\/eje.1.01821","article-title":"Plasma adiponectin is decreased in nonalcoholic fatty liver disease","volume":"152","author":"Pagano","year":"2005","journal-title":"Eur J Endocrinol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"e22709","DOI":"10.1002\/jcla.22709","article-title":"Low serum adiponectin is a predictor of progressing to nonalcoholic fatty liver disease","volume":"33","author":"Zhang","year":"2019","journal-title":"J Clin Lab Anal."},{"key":"B45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab."}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T08:34:36Z","timestamp":1600331676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fendo.2020.00654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":45,"alternative-id":["10.3389\/fendo.2020.00654"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2020.00654","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"article-number":"654"}}